product name Salinomycin
Description: Salinomycin (also known as Procoxacin, AHR-3096, Procoxacin) is an antibacterial and coccidiostat ionophore therapeutic agent. Salinomycin (Procoxacin) has been shown by Piyush Gupta to kill breast cancer stem cells at least 100 times more effectively than another popular anti-cancer compound (paclitaxel) in mice. The mechanism of action by which salinomycin (Procoxacin) kills cancer stem cells specifically remains unknown, but is thought to be due to its action as a potassium ionophore due to the detection of Nigericin in the same compound screen. Salinomycin has high toxicity and a narrow therapeutic window which may limit its clinical use.
References: J Antibiot (Tokyo). 1974 Nov;27(11):814-21; Chem Biol Drug Des. 2012 Mar;79(3):235-8.
751.00
Formula
C42H70O11
CAS No.
53003-10-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
Procoxacin, AHR-3096
other peoduct :
| In Vitro |
In vitro activity: Salinomycin (Procoxacin) is an antibacterial and coccidiostat ionophore therapeutic agent. Salinomycin (Procoxacin) has been shown by Piyush Gupta to kill breast cancer stem cells at least 100 times more effectively than another popular anti-cancer compound (paclitaxel) in mice. The mechanism of action by which salinomycin (Procoxacin) kills cancer stem cells specifically remains unknown, but is thought to be due to its action as a potassium ionophore due to the detection of Nigericin in the same compound screen. Salinomycin has high toxicity and a narrow therapeutic window which may limit its clinical use. Kinase Assay: Cell Assay: Several hepatocellular carcinoma (HCC) cell lines were treated with Sal. Results showed that Sal inhibited proliferation and decreased PCNA levels. Cell cycle analysis showed that Sal caused cell cycle arrest in different phases. Sal induced apoptosis as characterized by an increase in the Bax/Bcl-2 ratio. Compared to control, β-catenin expression was down-regulated by Sal treatment significantly. The Ca2+ concentration in HCC cells was examined by flow cytometry and it was found that higher Ca2+ concentrations were observed in Sal treatment groups. |
|---|---|
| In Vivo | The in vivo anti-tumor effect of Sal was verified using the hepatoma orthotopic tumor model and results showed that the liver tumor size in Sal-treated groups decreased. Immunohistochemistry and TUNEL staining also demonstrated that Sal could in vivo inhibit proliferation and induced apoptosis. |
| Animal model | |
| Formulation & Dosage | |
| References | J Antibiot (Tokyo). 1974 Nov;27(11):814-21; Chem Biol Drug Des. 2012 Mar;79(3):235-8. |
